Comparative Pharmacology
Head-to-head clinical analysis: NALOXONE HCL versus REVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALOXONE HCL versus REVEX.
NALOXONE HCL vs REVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Nalmefene is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, reversing or preventing opioid effects.
0.4 mg to 2 mg IV, IM, or subcutaneously, may repeat every 2-3 minutes as needed. For continuous infusion, IV infusion rate of 0.25-6.25 mg/hour.
0.5 mg to 1 mg intravenous, intramuscular, or subcutaneous, repeated every 2 to 5 minutes as needed, up to a maximum of 2 mg total dose per episode.
None Documented
None Documented
Terminal elimination half-life is 1.0-1.5 hours in adults. In neonates, half-life is prolonged (3-4 hours) due to immature hepatic function. Clinically, the short half-life necessitates repeated or continuous dosing to reverse opioid effects lasting longer than naloxone's duration.
Terminal elimination half-life: 2.4-4.2 hours in adults; prolonged in renal impairment (up to 50 hours).
Primarily hepatic metabolism (glucuronidation). Renal excretion accounts for approximately 50% of total clearance, with biliary/fecal elimination contributing 20-30%. Unchanged naloxone in urine is <5%.
Renal: 60% as unchanged drug and metabolites; fecal: 40% via biliary elimination.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist